WELCOME TO The Biotechnology REPORT
PCR (Phylasis Clinicas Research)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Labiotech | February 06, 2020
In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...
Skye Bioscience, Inc. | October 13, 2021
Skye Bioscience, Inc. (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing novel molecules that can affect the endocannabinoid system (ECS) for therapeutic benefit. The research in...
Ligand Pharmaceuticals | July 29, 2021
Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions.
The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wi...
Avantor | April 27, 2021
Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies.
In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE